510(k) Report

510(k) · Cleared

Recalled · Class II · 2014

Simplexa Flu a/B & RSV Direct, Simplexa Flu a/B & RSV Positive Control Pack

K120413510(k) TraditionalCleared Jul 13, 2012154-day reviewClass II21 CFR 866.3980Recalls 2

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Focus Diagnostics, Inc. · OCC Respiratory Virus Panel Nucleic Acid Assay System

Cleared on Jul 13, 2012 as substantially equivalent to K092500 (Prodesse, Inc., 2009) and 2 other predicates after a 154-day review. Its family tree reaches back 4 generations to 2008. 3 later devices descend from it. It has been recalled 2 times.

Decided
Jul 13, 2012
Review
154 days
Class
Class II
Product code
OCC
Recalls
2
Predicates
3

Its longest line of descent runs back 4 generations to DEN070013 (2008). 6 ancestors in all. 3 later devices descend from it, 2 citing it directly.

Other ancestors, by year clearedDescendants, by year cleared 2008: 2 other ancestors2016: 1 descendant cleared2014: 1 descendant cleared2015: 1 descendant clearedDEN070013 · ID-Tag Respiratory Viral Panel · Luminex Molecular Diagnostics, Inc. · 2008K081483 · Xtag Respiratory Viral Panel · Luminex Molecular Diagnostics, Inc. · 2008 · recalled×2: 2 generations cleared close together, K091667 (2009), K092500 (2009) 20052010201520202025
  1. Root · 4 generations backDEN070013 ID-Tag Respiratory Viral PanelLuminex Molecular Diagnostics, Inc. · 2008
  2. 3 generations backK081483 Xtag Respiratory Viral PanelLuminex Molecular Diagnostics, Inc. · 2008 · Recalled
  3. 2 generations backK091667 Xtag Respiratory Viral Panel, Models I019A0110, I019C011, I019D0112…Luminex Molecular Diagnostics, Inc. · 2009 · Recalled
  4. 1 generation backK092500 Modification to Proflu+ AssayProdesse, Inc. · 2009
  5. This deviceK120413 Simplexa Flu a/B & RSV Direct, Simplexa Flu a/B & RSV Positive…Focus Diagnostics, Inc. · 2012
  6. Descendant · cites it directly · 1 of its ownK142365 Simplexa Flu A/B & RSV Direct & Simplexa Flu A/B RSV Positive…Focus Diagnostics · 2014
  7. Descendant · cites it directly · 0 of its ownK161220 ARIES® Flu A/B & RSV AssayLuminex Corporation · 2016 · Recalled
  8. Descendant · 2 generations on · 0 of its ownK152408 Simplexa Flu A/B & RSV Direct and Simplexa Flu A/B & RSV Positive…Focus Diagnostics, Inc. · 2015 · Recalled

Most influential descendants

Showing 3 of 3 · See all
  • K142365Simplexa Flu A/B & RSV Direct & Simplexa Flu A/B RSV Positive Control PackFocus Diagnostics · 2014 · cites it directly1descendant
  • K161220ARIES® Flu A/B & RSV AssayLuminex Corporation · 2016 · cites it directly0descendants
  • K152408Simplexa Flu A/B & RSV Direct and Simplexa Flu A/B & RSV Positive Control PackFocus Diagnostics, Inc. · 2015 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4DEN070013ID-Tag Respiratory Viral PanelLuminex Molecular Diagnostics, Inc.2008—
−3K081483Xtag Respiratory Viral PanelLuminex Molecular Diagnostics, Inc.20081
−2K091667Xtag Respiratory Viral Panel, Models I019A0110, I019C011, I019D0112…Luminex Molecular Diagnostics, Inc.20091
−1K092500Modification to Proflu+ AssayProdesse, Inc.2009—
0 (this device)K120413Simplexa Flu a/B & RSV Direct, Simplexa Flu a/B & RSV Positive Control PackFocus Diagnostics, Inc.2012—
+1K142365Simplexa Flu A/B & RSV Direct & Simplexa Flu A/B RSV Positive Control PackFocus Diagnostics2014—
+1K161220ARIES® Flu A/B & RSV AssayLuminex Corporation20161
+2K152408Simplexa Flu A/B & RSV Direct and Simplexa Flu A/B & RSV Positive Control PackFocus Diagnostics, Inc.20151

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200820

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201410
201510
201610
FIG. 1 — Lineage of K120413, 2008–2016Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in OCC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new OCC device

  1. #1 K262747 ID NOW Influenza A & B 2; ID NOW RSV; ID NOW…score 15.2 · 12 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (3)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K092500Modification to Proflu+ Assay
Summary page 1
…ssay Product Code 0CC - respiratory virus panel nucleic acid assay system Predicate Devices Prodesse, ProFlu+ Assay (K092500, K081030, K073029) INTENDED USE The Focus Diagnostics Simplexa TmFlu A/B & RSV Direct assay is intended for use on the 3M Integr…
Prodesse, Inc.2009—
*K081030Modification to Proflu+ Assay
Summary page 1
…uct Code 0CC - respiratory virus panel nucleic acid assay system Predicate Devices Prodesse, ProFlu+ Assay (K092500, K081030, K073029) INTENDED USE The Focus Diagnostics Simplexa TmFlu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycl…
Prodesse, Inc.2008—
*K073029Proflu+ Assay
Summary page 1
…0CC - respiratory virus panel nucleic acid assay system Predicate Devices Prodesse, ProFlu+ Assay (K092500, K081030, K073029) INTENDED USE The Focus Diagnostics Simplexa TmFlu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycler instru…
Prodesse, Inc.2008—

Also cleared against K092500: 9 other devices →

What descends from it? (3)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K142365Simplexa Flu A/B & RSV Direct & Simplexa Flu A/B RSV Positive Control PackFocus Diagnostics20141
K161220ARIES® Flu A/B & RSV AssayLuminex Corporation20160

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
May 15, 2014Class IIZ-1958-2014Device DesignFocus Diagnostics is providing an urgent safety notice for a correction to the labeling for Simplexa" Flu A/B & RSV Direct (MOL2650). Focus Diagnostics received some customer complaints of Simplexa Flu A/B & RSV Direct assays with…
Jan 10, 2014Class IIZ-0846-2014PendingFocus Diagnostics is initiating an urgent safety notice correction for Simplexa Flu A/B & RSV Direct assay (MOL2650) because Focus Diagnostics has received some customer complaints of Simplexa Flu A/B & RSV lots due to sporadic false…

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 3 companies; a new generation was cleared every 12 months on median.
  • 2 of the 6 ancestors have a recall of any class.
  • Of its descendants, K142365 (Focus Diagnostics, 2014) has gone furthest, with 1 descendant of its own.
  • 9 other devices also cite its predicate K092500.

How does its category compare?

All OCC devices

OCC Respiratory Virus Panel Nucleic Acid Assay System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2012, this device’s year, is highlighted.

FDA decisions per year · OCC

1in 2024

2008: 42009: 62010: 22011: 92012: 62013: 62014: 42015: 82016: 72017: 102018: 42019: 52020: 22021: 12022: 12023: 22024: 12026 (partial year): 3
2007high 10 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · OCC

31in 2019

2008: 28 days median2009: 24 days median2011: 82 days median2012: 125 days median2013: 79 days median2014: 94 days median2015: 85 days median2016: 92 days median2017: 136 days median2018: 134 days median2019: 31 days median2026 (partial year): 130 days median
2007high 136 (2017) · low 24 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · OCC

1in 2024

2014: 12018: 12019: 12024: 1
2007high 1 (2014) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · OCC

2in 2025

2011: 22012: 12014: 522015: 12016: 362017: 12018: 12019: 22020: 172021: 6862022: 22023: 12024: 32025: 2
2007high 686 (2021) · low 0 (2007)2025

MAUDE reports naming product code OCC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
200842800
200962400
20102—00
201198202
2012612501
201367900
2014494152
201588501
2016792036
20171013601
2018413411
201953112
20202—017
20211—0686
20221—02
20232—01
20241—13
20250—02
202631300—

What is it indicated for?

The Focus Diagnostics Simplexa Flu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycler instrument for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use…

Read the full statement (271 words)

The Focus Diagnostics Simplexa Flu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycler instrument for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use as an aid in the differential diagnosis of influenza A, influenza B, and RSV viral infections in humans and is not intended to detect influenza C.

Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established with clinical specimens collected during the 2010/2011 influenza season when 2009 H1N1 influenza and H3N2 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to the state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

Focus Diagnostics' Simplexa Flu A/B & RSV Positive Control Pack is intended to be used as a control with the Simplexa Flu A/B & RSV Direct kit. This control is not intended for use with other assays or systems.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K120413: Simplexa Flu a/B & RSV Direct, Simplexa Flu a/B & RSV Positive Control Pack.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K120413

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026